Search Results - "Qi, Rongqin"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Retraction notice to “Controlled delivery of ketamine from reduced graphene oxide hydrogel for neuropathic pain: In vitro and in vivo studies” [J. Drug Deliv. Sci. Technol. 60 (2020) 101964] by Wang, Rui, Gan, Jianhu, Li, Renhu, Duan, Jinghui, Zhou, Jianjun, Lv, Miaomiao, Qi, Rongqin

    “…This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been…”
    Get full text
    Journal Article
  2. 2

    Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8+ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression by Bu, Meimei, Shen, Yizhen, Seeger, William L., An, Shizhi, Qi, Rongqin, Sanderson, Joanna A., Cai, Yan

    Published in Tumor biology (01-03-2016)
    “…Ovarian carcinoma is one of the most severe cancers in women, with a high relapse rate and limited secondary treatment options. To assist research in novel…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8 super(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression by Bu, Meimei, Shen, Yizhen, Seeger, William L, An, Shizhi, Qi, Rongqin, Sanderson, Joanna A, Cai, Yan

    Published in Tumor biology (01-03-2016)
    “…Ovarian carcinoma is one of the most severe cancers in women, with a high relapse rate and limited secondary treatment options. To assist research in novel…”
    Get full text
    Journal Article
  5. 5

    Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8^sup +^ T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression by Bu, Meimei, Shen, Yizhen, Seeger, William L, An, Shizhi, Qi, Rongqin, Sanderson, Joanna A, Cai, Yan

    Published in Tumor biology (01-03-2016)
    “…Ovarian carcinoma is one of the most severe cancers in women, with a high relapse rate and limited secondary treatment options. To assist research in novel…”
    Get full text
    Journal Article